ALX Oncology Cuts Workforce to Optimize Resources ALX Oncology is reducing its workforce by 30%, focusing on prioritizing its CD47-blocker, evorpacept, and other key programs. The company anticipates extending its cash runway into late 2025 through this strategic move, which aligns with its efforts to streamline operations and focus on its most promising assets.3